- Schimmel M, Nur E, Mairuhu W, Brandjes DPM, Olde Engberink RHG, Vogt L, Biemond BJ, Urinary zinc loss in sickle cell disease primarily due to increased bone degradation. AM J HEMATOL 2016;91 (6):E311-E312 [PubMed]
- Schimmel M, van Beers EJ, van Tuijn CFJ, Nur E, Rijneveld AW, Mac Gillavry MR, Brandjes DPB, Schnog JJB, Biemond BJ, N-terminal pro-B-type natriuretic peptide, tricuspid jet flow velocity, and death in adults with sickle cell disease. AM J HEMATOL 2015;90 (4):E75-E76 [PubMed]
- Nur E, van Beers EJ, Martina S, Cuccovillo I, Otten HM, Schnog JJB, Meijers JCM, Mantovani A, Brandjes DP, Bottazzi B, Biemond BJ, Plasma levels of pentraxin-3, an acute phase protein, are increased during sickle cell painful crisis. BLOOD CELL MOL DIS 2011;46 (3):189-194 [PubMed]
- Lauw MN, Bus EWN, van Wulfften Palthe AFY, Coppens M, Homburg CH, Middeldorp S, van der Schoot CE, Koene HR, Biemond BJ, Relevance of the JAK2V617F mutation in patients with deep vein thrombosis of the leg. ANN HEMATOL 2012;91 (1):103-107 [PubMed]
- Lauw MN, van der Holt B, Middeldorp S, Meijers JCM, Cornelissen JJ, Biemond BJ, Venous thromboembolism in adults treated for acute lymphoblastic leukaemia: Effect of fresh frozen plasma supplementation. THROMB HAEMOSTASIS 2013;109 (4):633-642 [PubMed]
Bart Biemond is working in the Academic Medical Center as senior staff member of the Department of Hematology and responsible for general hematological care and education (both benign and hemato-oncology). He has been working as an internist hematologist for 15 years and is involved in patient care, supervision of hematology fellows and residents. Furthermore, he is working as a consultant for hematology in the Flevo Hospital in Almere and the OLVG Hospital in Amsterdam. His focus of research is sickle cell disease and coagulopathy in patients with hematological malignancies. As a member of the CURAMA and Score study group he has focused on clinical and pre-clinical studies on vasculopathy in SCD. Moreover, he is active member of the acute leukemia and benign hematology working group of HOVON.
Vasculopathy in sickle cell disease/Coagulopathy in hemotological malignancies
The coming 5 years research will focus on: 1. the value of specific biomarkers in SCD; 2. evaluation of the development of organ damage in SCD; and 3. performing intervention studies to test new therapies to prevent or treat vaso-occlusive crises.Ad 1.
The biomarker studies will help to determine specific risk groups, but may also be helpful in the understanding of the pathogenesis of SCD. Specific biomarkers of interest are: nucleosomes, zinc and pentaxine-3. In a recent study nucleosomes have been demonstrated to play an important role in the inflammatory response in sickle cell disease crises. Future studies will aim at the source of these nucleosomes and the exact mechanism by which they are related to the inflammatory response and endothelial damage. Ad 2.
Clinical studies will focus on specific complications of SCD. In particular, the prevention of acute chest syndrome (an often fatal complication of sickle cell diseas) by incentive spirometry and the detection of liver fibrosis due to recurrent vaso-occlusion will be the main target for the coming years. The value of spirometry will be tested prospectively and a large cross sectional study with the use of the Fibroscan will be performed to evaluate the increasing frequency of liver failure in relative young sickle cell patients for which no clear explanation could be found. Ad 3.
Different intervention studies to test new therapeutic strategies are planned for the coming years. First, a multicentre study will start this year to study the effect of the antioxidant n-acetylcysteine on the prevention of sickle cell crises and daily pain. A smaller phase 2 intervention study will be performed to evaluate the effect of vitamin D suppletion on daily pain which may be caused by osteomalacia due to vitamin D deficiency which is very prevalent in SCD. Within a recently started European collaboration a large randomized controlled trial is currently being designed to assess the effect of a selective p-selectine inhibitor in the treatment of patients with a sickle cell crisis. The AMC will be the leading centre in this European collaboration.
Prof. dr. B.J. Biemond
F.E.H.P. van Baarle
L. Václavů MSc
Drs. E.K. van de Weerdt
Drs. I.L.M. Klaassen
Prof. dr. M.H.J. van Oers (Pathogenesis and Immunotherapy of B cell malignancies)
- Contribution to guidelines and protocols, Dutch guidelines for CML treatment
- Contribution to guidelines and protocols, Dutch guidelines for Myeloproliferative neoplasms
- Contribution to guidelines and protocols, Dutch guidelines for diagnosis and treatment of MDS
- Membership of medical or scientific committee, HOVON, Board member
- Contribution to guidelines and protocols, Dutch guidelines for sickle cell disease
- Contribution to guidelines and protocols, Dutch guidelines for blood transfusion
- Amgen BV
- Ergomed Clinical Research PLC
- Global Blood Therapeutics
- IQVIA RDS Netherlands B.V.
- Karyopharm Therapeutics Inc.
- Roche Nederland B.V.
- Stichting AMC Foundation
- Stichting Hematologisch Oncologische Wetenschap
- Stichting Hovon Amsterdam, p/a VUmc
- Swedish Orphan Biovitrum BVBA/SPRL
- UMC Utrecht